Korea Q3 Roundup: Record Quarter For Hanmi, Daewoong, Boryung
US Approval For Hanmi’s Rolvedon
Aside from what was generally a strong quarter for South Korean biopharma firms, Hanmi faces mixed news for its US pipeline, Daewoong’s Fexuclue and Nabota expand their market presence, Boryung builds its oncology business and SK Bioscience unveils an updated growth strategy.
You may also be interested in...
Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.
South Korea's breakthrough therapy system, Global Innovative Products Fast Track, kicks off with Roche’s follicular lymphoma drug becoming the first to test the new system. Meanwhile, a state-run group is linking with pharma firms to rapidly bring in global new drugs.
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.